Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9328390 | Gynecologic Oncology | 2005 | 4 Pages |
Abstract
While the indolent clinical course of thyomoma frequently necessitates re-treatment and multi-modality therapy in patients suffering recurrences, treatment selection must take into account potential long-term morbidity and attendant quality of life. When anatomically and technically feasible, resection of recurrent disease should be considered in attempts to avoid potential cumulative and long-term toxicity resultant from radiotherapy and chemotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Kevin S. Elliott, Mark E. Borowsky, Khldoun Bakdounes, Jennifer Huang, Ovadia Abulafia, Yi-Chun Lee,